Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | IQVIA Holdings Inc. P/E ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023. |
P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | IQVIA Holdings Inc. P/OP ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023. |
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | IQVIA Holdings Inc. P/S ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023. |
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | IQVIA Holdings Inc. P/BV ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023. |
Price to Earnings (P/E)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 182,500,000 | 183,122,255 | 185,549,128 | 185,722,621 | 185,740,023 | 186,507,930 | 189,279,035 | 190,485,264 | 191,039,501 | 191,612,337 | 191,661,174 | 191,281,286 | 191,725,778 | 191,270,966 | 190,963,771 | 192,339,093 | 194,037,571 | 195,894,501 | 197,240,698 | 197,599,861 | 202,306,281 | 202,586,895 | 207,684,876 | |||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
Net income (loss) attributable to IQVIA Holdings Inc. (in millions) | 303) | 297) | 289) | 227) | 283) | 256) | 325) | 318) | 261) | 175) | 212) | 119) | 101) | (23) | 82) | 16) | 57) | 60) | 58) | 69) | 60) | 61) | 69) | |||||||
Earnings per share (EPS)2 | 6.12 | 5.99 | 5.69 | 5.87 | 6.36 | 6.22 | 5.70 | 5.07 | 4.01 | 3.17 | 2.13 | 1.46 | 0.92 | 0.69 | 1.13 | 0.99 | 1.26 | 1.26 | 1.26 | 1.31 | 0.00 | 0.00 | 0.00 | |||||||
Share price1, 3 | 180.01 | 219.13 | 188.23 | 227.03 | 200.42 | 221.74 | 219.40 | 232.18 | 256.89 | 245.37 | 232.30 | 192.66 | 169.40 | 161.48 | 142.59 | 165.42 | 146.74 | 160.61 | 136.14 | 141.49 | 119.92 | 120.45 | 99.02 | |||||||
Valuation Ratio | ||||||||||||||||||||||||||||||
P/E ratio4 | 29.44 | 36.61 | 33.11 | 38.65 | 31.49 | 35.65 | 38.49 | 45.78 | 63.98 | 77.46 | 108.86 | 132.09 | 184.54 | 233.99 | 126.65 | 166.58 | 116.69 | 127.38 | 108.28 | 107.95 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
P/E Ratio, Competitors5 | ||||||||||||||||||||||||||||||
AbbVie Inc. | 38.27 | 30.55 | 34.43 | 22.62 | 19.16 | 19.44 | 21.64 | 22.07 | 27.34 | 30.62 | 39.63 | 40.17 | 22.60 | 23.92 | 14.70 | 17.82 | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 18.09 | 16.31 | 16.18 | 19.56 | 21.00 | 20.03 | 22.23 | 21.05 | 21.91 | 22.56 | 19.20 | 18.82 | 17.25 | 19.97 | 17.70 | 17.07 | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 13.01 | 15.93 | 19.43 | 23.97 | 23.71 | 24.14 | 25.64 | 20.92 | — | — | — | — | — | — | 144.77 | 41.99 | — | — | — | — | — | — | — | |||||||
Danaher Corp. | 24.76 | 29.99 | 25.00 | 25.65 | 26.65 | 32.73 | 32.15 | 29.94 | 38.81 | 37.87 | 39.26 | 44.49 | 46.61 | 41.91 | 35.88 | 38.34 | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 110.43 | 76.21 | 65.16 | 50.08 | 55.53 | 51.05 | 45.29 | 40.66 | 40.07 | 40.34 | 28.77 | 31.95 | 22.54 | 25.59 | 26.56 | 16.19 | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 17.10 | 17.88 | 17.75 | 22.68 | 29.30 | 18.66 | 17.25 | 12.36 | 11.44 | 16.83 | 277.25 | 641.48 | 59.19 | — | 19.58 | 16.45 | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 10.12 | 33.35 | 33.43 | 22.97 | 23.52 | 24.98 | 23.95 | 20.93 | 23.98 | 25.51 | 28.35 | 28.92 | 22.51 | 25.68 | 23.06 | 25.99 | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 56.85 | 86.53 | 22.92 | 19.21 | 16.41 | 13.36 | 15.70 | 14.78 | 28.65 | 34.23 | 28.00 | 26.72 | 17.67 | 19.70 | 19.18 | 20.60 | — | — | — | — | — | — | — | |||||||
Moderna Inc. | — | 34.67 | 10.70 | 6.43 | 4.82 | 5.19 | 4.21 | 5.00 | 16.31 | 48.08 | 107.74 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 16.60 | 9.42 | 7.44 | 7.58 | 8.81 | 9.56 | 11.11 | 11.76 | 14.03 | 20.05 | 20.15 | 19.62 | 25.36 | 14.99 | 13.04 | 11.63 | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 22.35 | 19.48 | 19.77 | 19.68 | 14.98 | 11.67 | 9.15 | 8.37 | 9.96 | 10.38 | 13.27 | 15.09 | 19.91 | 22.27 | 28.35 | 19.86 | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 29.57 | 37.01 | 34.99 | 30.55 | 27.64 | 31.09 | 28.15 | 27.35 | 29.43 | 24.63 | 23.23 | 27.89 | 38.43 | 44.19 | 35.50 | 33.36 | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
EPS
= (Net income (loss) attributable to IQVIA Holdings Inc.Q3 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q2 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q1 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q4 2022)
÷ No. shares of common stock outstanding
= (303,000,000 + 297,000,000 + 289,000,000 + 227,000,000)
÷ 182,500,000 = 6.12
3 Closing price as at the filing date of IQVIA Holdings Inc. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/E ratio = Share price ÷ EPS
= 180.01 ÷ 6.12 = 29.44
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | IQVIA Holdings Inc. P/E ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023. |
Price to Operating Profit (P/OP)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 182,500,000 | 183,122,255 | 185,549,128 | 185,722,621 | 185,740,023 | 186,507,930 | 189,279,035 | 190,485,264 | 191,039,501 | 191,612,337 | 191,661,174 | 191,281,286 | 191,725,778 | 191,270,966 | 190,963,771 | 192,339,093 | 194,037,571 | 195,894,501 | 197,240,698 | 197,599,861 | 202,306,281 | 202,586,895 | 207,684,876 | |||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
Income from operations (in millions) | 481) | 524) | 471) | 379) | 472) | 453) | 495) | 463) | 302) | 286) | 342) | 289) | 187) | 62) | 193) | 166) | 204) | 197) | 210) | 207) | 181) | 170) | 183) | |||||||
Operating profit per share2 | 10.16 | 10.08 | 9.57 | 9.69 | 10.14 | 9.18 | 8.17 | 7.31 | 6.38 | 5.76 | 4.59 | 3.82 | 3.17 | 3.27 | 3.98 | 4.04 | 4.22 | 4.06 | 3.89 | 3.75 | 0.00 | 0.00 | 0.00 | |||||||
Share price1, 3 | 180.01 | 219.13 | 188.23 | 227.03 | 200.42 | 221.74 | 219.40 | 232.18 | 256.89 | 245.37 | 232.30 | 192.66 | 169.40 | 161.48 | 142.59 | 165.42 | 146.74 | 160.61 | 136.14 | 141.49 | 119.92 | 120.45 | 99.02 | |||||||
Valuation Ratio | ||||||||||||||||||||||||||||||
P/OP ratio4 | 17.71 | 21.74 | 19.68 | 23.44 | 19.77 | 24.14 | 26.86 | 31.75 | 40.26 | 42.59 | 50.59 | 50.41 | 53.42 | 49.42 | 35.83 | 40.95 | 34.81 | 39.58 | 34.96 | 37.73 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
P/OP Ratio, Competitors5 | ||||||||||||||||||||||||||||||
AbbVie Inc. | 16.55 | 15.26 | 16.15 | 14.78 | 14.52 | 14.12 | 14.57 | 14.21 | 12.41 | 13.12 | 17.23 | 16.32 | 14.42 | 15.23 | 9.13 | 10.82 | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 15.45 | 13.71 | 14.25 | 13.40 | 14.89 | 14.08 | 15.88 | 16.24 | 16.73 | 17.48 | 15.26 | 14.96 | 13.82 | 15.84 | 14.22 | 13.84 | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 14.14 | 16.24 | 17.09 | 18.29 | 17.79 | 18.62 | 20.32 | 19.84 | — | — | — | — | 39.45 | 33.97 | 27.33 | 24.42 | — | — | — | — | — | — | — | |||||||
Danaher Corp. | 23.61 | 27.01 | 21.31 | 20.97 | 20.71 | 25.91 | 26.48 | 25.14 | 32.12 | 30.83 | 32.62 | 36.91 | 46.28 | 43.09 | 35.22 | 34.47 | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 93.27 | 69.42 | 59.60 | 43.88 | 46.48 | 39.20 | 36.49 | 35.70 | 37.21 | 42.01 | 31.17 | 32.66 | 22.98 | 25.58 | 24.82 | 27.08 | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 12.16 | 11.57 | 11.21 | 14.21 | 16.27 | 11.02 | 10.78 | 7.76 | 7.27 | 8.88 | 18.31 | 19.38 | 29.86 | — | 21.83 | 20.66 | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 15.69 | 18.91 | 18.26 | 17.62 | 19.64 | 20.45 | 21.06 | 18.68 | 18.99 | 20.14 | 21.12 | 21.84 | 19.46 | 19.66 | 18.67 | 19.83 | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 33.75 | 44.67 | 18.53 | 15.55 | 13.85 | 11.72 | 14.29 | 15.39 | 30.71 | 38.03 | 30.14 | 23.89 | 16.00 | 17.23 | 15.88 | 17.47 | — | — | — | — | — | — | — | |||||||
Moderna Inc. | — | 81.57 | 10.61 | 5.71 | 4.28 | 4.66 | 3.79 | 4.59 | 15.13 | 44.01 | 101.69 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 17.49 | 9.17 | 6.74 | 6.80 | 7.82 | 9.11 | 11.49 | 13.30 | 16.37 | 19.83 | 22.85 | 23.12 | 22.27 | 22.17 | 17.42 | 14.36 | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 21.13 | 19.32 | 18.68 | 18.01 | 12.91 | 9.68 | 7.98 | 7.55 | 9.32 | 9.65 | 13.32 | 14.82 | 20.36 | 23.98 | 26.60 | 19.01 | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 25.59 | 31.55 | 29.54 | 25.30 | 21.43 | 23.99 | 21.84 | 21.07 | 23.87 | 19.77 | 18.53 | 22.81 | 31.49 | 36.59 | 28.44 | 26.84 | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
Operating profit per share
= (Income from operationsQ3 2023
+ Income from operationsQ2 2023
+ Income from operationsQ1 2023
+ Income from operationsQ4 2022)
÷ No. shares of common stock outstanding
= (481,000,000 + 524,000,000 + 471,000,000 + 379,000,000)
÷ 182,500,000 = 10.16
3 Closing price as at the filing date of IQVIA Holdings Inc. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 180.01 ÷ 10.16 = 17.71
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | IQVIA Holdings Inc. P/OP ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023. |
Price to Sales (P/S)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 182,500,000 | 183,122,255 | 185,549,128 | 185,722,621 | 185,740,023 | 186,507,930 | 189,279,035 | 190,485,264 | 191,039,501 | 191,612,337 | 191,661,174 | 191,281,286 | 191,725,778 | 191,270,966 | 190,963,771 | 192,339,093 | 194,037,571 | 195,894,501 | 197,240,698 | 197,599,861 | 202,306,281 | 202,586,895 | 207,684,876 | |||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
Revenues (in millions) | 3,736) | 3,728) | 3,652) | 3,739) | 3,562) | 3,541) | 3,568) | 3,636) | 3,391) | 3,438) | 3,409) | 3,298) | 2,786) | 2,521) | 2,754) | 2,895) | 2,769) | 2,740) | 2,684) | 2,688) | 2,594) | 2,567) | 2,563) | |||||||
Sales per share2 | 81.40 | 80.17 | 78.11 | 77.59 | 77.03 | 75.79 | 74.14 | 72.84 | 70.85 | 67.49 | 62.68 | 59.38 | 57.14 | 57.19 | 58.43 | 57.65 | 56.08 | 54.65 | 53.40 | 52.69 | 0.00 | 0.00 | 0.00 | |||||||
Share price1, 3 | 180.01 | 219.13 | 188.23 | 227.03 | 200.42 | 221.74 | 219.40 | 232.18 | 256.89 | 245.37 | 232.30 | 192.66 | 169.40 | 161.48 | 142.59 | 165.42 | 146.74 | 160.61 | 136.14 | 141.49 | 119.92 | 120.45 | 99.02 | |||||||
Valuation Ratio | ||||||||||||||||||||||||||||||
P/S ratio4 | 2.21 | 2.73 | 2.41 | 2.93 | 2.60 | 2.93 | 2.96 | 3.19 | 3.63 | 3.64 | 3.71 | 3.24 | 2.96 | 2.82 | 2.44 | 2.87 | 2.62 | 2.94 | 2.55 | 2.69 | — | — | — | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
P/S Ratio, Competitors5 | ||||||||||||||||||||||||||||||
AbbVie Inc. | 4.52 | 4.74 | 4.60 | 4.61 | 4.44 | 4.28 | 4.76 | 4.53 | 3.73 | 3.80 | 4.07 | 4.05 | 4.10 | 4.59 | 3.64 | 4.22 | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 5.34 | 5.14 | 5.14 | 5.17 | 5.85 | 5.35 | 5.21 | 5.10 | 5.04 | 5.37 | 5.68 | 5.64 | 5.33 | 6.30 | 5.96 | 6.03 | — | — | — | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 2.40 | 2.81 | 3.10 | 3.29 | 3.39 | 3.39 | 3.41 | 3.16 | 2.85 | 3.44 | 3.28 | 3.16 | 3.66 | 3.97 | 4.45 | 5.52 | — | — | — | — | — | — | — | |||||||
Danaher Corp. | 5.63 | 6.77 | 5.76 | 5.79 | 5.66 | 6.59 | 6.68 | 6.37 | 7.91 | 7.72 | 7.27 | 7.01 | 8.15 | 7.48 | 6.34 | 6.29 | — | — | — | — | — | — | — | |||||||
Eli Lilly & Co. | 17.18 | 16.78 | 13.38 | 10.96 | 11.46 | 9.99 | 9.47 | 8.01 | 8.62 | 9.16 | 6.88 | 8.06 | 5.41 | 6.26 | 6.36 | 6.03 | — | — | — | — | — | — | — | |||||||
Gilead Sciences Inc. | 3.69 | 3.61 | 3.70 | 3.86 | 3.64 | 2.84 | 2.86 | 2.85 | 3.11 | 3.30 | 3.31 | 3.24 | 3.29 | 3.95 | 4.34 | 4.00 | — | — | — | — | — | — | — | |||||||
Johnson & Johnson | 4.01 | 4.84 | 4.60 | 4.34 | 4.69 | 4.80 | 5.00 | 4.66 | 4.69 | 5.08 | 5.09 | 5.15 | 4.73 | 4.84 | 4.78 | 4.79 | — | — | — | — | — | — | — | |||||||
Merck & Co. Inc. | 4.42 | 4.62 | 5.16 | 4.71 | 4.25 | 3.87 | 4.12 | 3.96 | 4.32 | 4.05 | 4.23 | 3.93 | 4.30 | 4.38 | 4.05 | 4.33 | — | — | — | — | — | — | — | |||||||
Moderna Inc. | 3.38 | 4.14 | 3.57 | 2.92 | 2.76 | 3.29 | 2.82 | 3.45 | 10.53 | 27.41 | 33.34 | 309.64 | — | — | — | — | — | — | — | — | — | — | — | |||||||
Pfizer Inc. | 2.51 | 2.58 | 2.32 | 2.37 | 2.63 | 2.77 | 3.00 | 3.18 | 4.04 | 4.78 | 4.84 | 4.50 | 4.71 | 4.69 | 4.21 | 3.66 | — | — | — | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 6.81 | 6.61 | 6.69 | 7.01 | 5.87 | 4.66 | 4.40 | 4.20 | 5.14 | 5.20 | 5.78 | 6.24 | 7.62 | 8.31 | 8.10 | 5.34 | — | — | — | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 4.05 | 4.87 | 4.81 | 4.73 | 4.40 | 5.40 | 5.20 | 5.39 | 6.45 | 5.54 | 5.13 | 5.52 | 6.58 | 6.24 | 5.08 | 4.83 | — | — | — | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
Sales per share
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ No. shares of common stock outstanding
= (3,736,000,000 + 3,728,000,000 + 3,652,000,000 + 3,739,000,000)
÷ 182,500,000 = 81.40
3 Closing price as at the filing date of IQVIA Holdings Inc. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/S ratio = Share price ÷ Sales per share
= 180.01 ÷ 81.40 = 2.21
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | IQVIA Holdings Inc. P/S ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023. |
Price to Book Value (P/BV)
Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. shares of common stock outstanding1 | 182,500,000 | 183,122,255 | 185,549,128 | 185,722,621 | 185,740,023 | 186,507,930 | 189,279,035 | 190,485,264 | 191,039,501 | 191,612,337 | 191,661,174 | 191,281,286 | 191,725,778 | 191,270,966 | 190,963,771 | 192,339,093 | 194,037,571 | 195,894,501 | 197,240,698 | 197,599,861 | 202,306,281 | 202,586,895 | 207,684,876 | |||||||
Selected Financial Data (US$) | ||||||||||||||||||||||||||||||
Equity attributable to IQVIA Holdings Inc.’s stockholders (in millions) | 5,805) | 5,748) | 5,932) | 5,765) | 5,347) | 5,352) | 5,919) | 6,042) | 5,829) | 5,760) | 5,953) | 6,001) | 5,846) | 5,591) | 5,542) | 6,003) | 6,131) | 6,523) | 6,615) | 6,714) | 7,215) | 7,364) | 8,196) | |||||||
Book value per share (BVPS)2 | 31.81 | 31.39 | 31.97 | 31.04 | 28.79 | 28.70 | 31.27 | 31.72 | 30.51 | 30.06 | 31.06 | 31.37 | 30.49 | 29.23 | 29.02 | 31.21 | 31.60 | 33.30 | 33.54 | 33.98 | 35.66 | 36.35 | 39.46 | |||||||
Share price1, 3 | 180.01 | 219.13 | 188.23 | 227.03 | 200.42 | 221.74 | 219.40 | 232.18 | 256.89 | 245.37 | 232.30 | 192.66 | 169.40 | 161.48 | 142.59 | 165.42 | 146.74 | 160.61 | 136.14 | 141.49 | 119.92 | 120.45 | 99.02 | |||||||
Valuation Ratio | ||||||||||||||||||||||||||||||
P/BV ratio4 | 5.66 | 6.98 | 5.89 | 7.31 | 6.96 | 7.73 | 7.02 | 7.32 | 8.42 | 8.16 | 7.48 | 6.14 | 5.56 | 5.52 | 4.91 | 5.30 | 4.64 | 4.82 | 4.06 | 4.16 | 3.36 | 3.31 | 2.51 | |||||||
Benchmarks | ||||||||||||||||||||||||||||||
P/BV Ratio, Competitors5 | ||||||||||||||||||||||||||||||
AbbVie Inc. | 20.61 | 20.62 | 19.68 | 15.52 | 16.06 | 16.76 | 16.59 | 16.53 | 15.20 | 16.23 | 14.91 | 14.18 | 10.93 | 11.31 | — | — | — | — | — | — | — | — | — | |||||||
Amgen Inc. | 17.87 | 19.19 | 23.95 | 35.01 | 39.30 | 54.46 | 138.87 | 18.51 | 14.95 | 15.72 | 14.57 | 14.53 | 11.57 | 13.67 | 14.33 | 13.84 | 11.47 | 10.37 | 9.92 | — | — | — | — | |||||||
Bristol-Myers Squibb Co. | 3.72 | 3.97 | 4.46 | 4.88 | 4.85 | 4.90 | 5.07 | 4.07 | 3.48 | 4.15 | 3.73 | 3.55 | 2.87 | 2.82 | 2.77 | 2.80 | 5.30 | 4.63 | 4.91 | — | — | — | — | |||||||
Danaher Corp. | 2.78 | 3.65 | 3.33 | 3.64 | 3.77 | 4.36 | 4.36 | 4.16 | 5.11 | 4.82 | 4.46 | 3.93 | 4.38 | 3.90 | 3.68 | 3.72 | 3.02 | 3.19 | 2.88 | — | — | — | — | |||||||
Eli Lilly & Co. | 49.10 | 44.75 | 33.11 | 29.36 | 33.27 | 34.00 | 29.75 | 25.28 | 30.85 | 38.00 | 25.41 | 35.07 | 26.02 | 35.12 | 47.73 | 51.67 | 31.28 | 39.03 | 46.37 | — | — | — | — | |||||||
Gilead Sciences Inc. | 4.50 | 4.63 | 4.72 | 4.90 | 4.63 | 3.82 | 3.91 | 3.65 | 3.94 | 4.41 | 4.40 | 4.33 | 4.30 | 4.79 | 4.40 | 3.93 | 4.02 | 3.58 | 3.83 | — | — | — | — | |||||||
Johnson & Johnson | 4.92 | 5.79 | 6.00 | 5.37 | 6.04 | 6.01 | 6.36 | 5.90 | 6.10 | 6.51 | 6.51 | 6.72 | 5.93 | 6.19 | 6.46 | 6.61 | 5.84 | 5.78 | 6.39 | — | — | — | — | |||||||
Merck & Co. Inc. | 6.35 | 6.96 | 6.38 | 6.07 | 5.63 | 5.12 | 5.44 | 5.05 | 5.76 | 5.73 | 7.30 | 7.46 | 6.97 | 7.47 | 7.43 | 7.83 | 7.87 | 7.82 | 7.31 | — | — | — | — | |||||||
Moderna Inc. | 2.20 | 2.47 | 2.71 | 2.81 | 3.15 | 4.06 | 3.61 | 4.31 | 11.37 | 25.06 | 16.79 | 24.16 | 9.67 | 9.88 | 12.03 | 8.21 | 4.29 | 3.25 | 5.29 | — | — | — | — | |||||||
Pfizer Inc. | 1.80 | 2.04 | 2.14 | 2.48 | 2.83 | 3.21 | 3.37 | 3.35 | 3.69 | 3.78 | 3.27 | 2.98 | 3.10 | 3.31 | 3.16 | 3.00 | 3.14 | 3.42 | 3.84 | — | — | — | — | |||||||
Regeneron Pharmaceuticals Inc. | 3.58 | 3.49 | 3.52 | 3.77 | 3.75 | 3.21 | 3.65 | 3.60 | 4.04 | 4.26 | 4.44 | 4.81 | 6.21 | 7.34 | 5.33 | 3.79 | 3.48 | 3.38 | 3.74 | — | — | — | — | |||||||
Thermo Fisher Scientific Inc. | 3.88 | 4.84 | 4.99 | 4.83 | 4.46 | 5.47 | 5.23 | 5.18 | 6.51 | 5.75 | 5.25 | 5.15 | 5.89 | 5.48 | 4.56 | 4.16 | 4.15 | 3.83 | 4.02 | — | — | — | — |
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
BVPS = Equity attributable to IQVIA Holdings Inc.’s stockholders ÷ No. shares of common stock outstanding
= 5,805,000,000 ÷ 182,500,000 = 31.81
3 Closing price as at the filing date of IQVIA Holdings Inc. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/BV ratio = Share price ÷ BVPS
= 180.01 ÷ 31.81 = 5.66
5 Click competitor name to see calculations.
Valuation ratio | Description | The company |
---|---|---|
P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. | IQVIA Holdings Inc. P/BV ratio increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023. |